Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7789 dose-escalation and expansion study in advanced or metastatic solid tumors
NL-OMON56048Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of sabestomig, sponsored by AstraZeneca. Started Nov 2022; status: recruiting.
02
Drugs
sabestomig
Beyond the preview
Go deeper on NL-OMON56048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56048.